Nabi Sells Biologics Business To German Plasma Protein Firm Biotest
This article was originally published in The Pink Sheet Daily
Executive Summary
Nabi met with FDA Sept. 11 concerning components and a timeline for completion of its Nabi-HB IV BLA, pending at the agency since 2002.
You may also be interested in...
GSK Coughs Up $40 M for Option on Nabi's Late-Stage Smoking Vaccine NicVAX
Glaxo must decide by end of Phase 3 whether to exercise its option for $58 million more, but either way it gets rights to develop a next-gen version.
GSK Coughs Up $40 M for Option on Nabi's Late-Stage Smoking Vaccine NicVAX
Glaxo must decide by end of Phase 3 whether to exercise its option for $58 million more, but either way it gets rights to develop a next-gen version.
Nabi Announces Plans To Evaluate Merger Or Sale Of Firm Under New CEO
Company refocuses on primary compounds, smoking-cessation vaccine NicVAX and Staphylococcus aureus vaccine StaphVax.